MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings

Bone Marrow Transplantation

Volumn 45, Issue 9, 2010, Pages 1449-1456

  Pinana J L ^a   Valcarcel D ^a   Fernandez Aviles F ^b   Martino, R ^a   Rovira, M ^b   Barba, P ^a   Martinez C ^b   Brunet, S ^a   Sureda, A ^a   Carreras, E ^b   Sierra, J ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

allo RIC; allo SCT; GVHD prophylaxis; MTX; mycophenolate mofetil; reduced intensity conditioning

Indexed keywords

ACICLOVIR; BUSULFAN; CIPROFLOXACIN; CYCLOSPORIN A; FLUCONAZOLE; FLUDARABINE; FOLINIC ACID; LEVOFLOXACIN; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; GRAFT RECIPIENT; HEMATOLOGIC MALIGNANCY; HLA SYSTEM; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVING DONOR; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SHORT COURSE THERAPY; SIBLING; STOMATITIS;

ADOLESCENT; ADULT; AGED; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; MIDDLE AGED; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES; SIBLINGS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 77956459654     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.362     Document Type: Article

References (36)

1. Valcarcel D, Martino R, Sureda A, Canals C, Altes A, Briones J et al. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. Eur J Haematol 2005; 74: 144-151.
2. Mielcarek M, Martin PJ, Leisenring W, Flowers M, Maloney D, Sandmaier B et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756-762.
3. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729-735. (Pubitemid 16124386)
4. Storb R, Deeg HJ, Pepe M, Appelbaum F, Anasetti C, Beatty P et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989; 73: 1729-1734. (Pubitemid 19131924)
5. Neumann F, Graef T, Tapprich C, Vaupel M, Steidl U, Germing U et al. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Bone Marrow Transplant 2005; 35: 1089-1093.
6. Cutler C, Li S, Kim HT, Laglenne P, Szeto K, Hoffmeister L et al. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate-and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant 2005; 11: 383-388.
7. Ho VT, Weller E, Lee SJ, Edwin P, Alyea E, Antin JH, Soiffer R et al. Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. Biol Blood and Marrow Transplant 2001; 7: 223-229.
8. Pinana JL, Valcarcel D, Martino R, Barba P, Moreno E, Sureda A et al. Study of kidney function impairment after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation A single centre experience. Biol Blood Marrow Transplant 2009; 15: 21-29.
9. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
10. Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004; 34: 621-625.
11. Bornhauser M, Schuller U, Porksen G, Geissler G, Thiede C, Schwerdtfeger R et al. Mycophenolate mofetil and cyclospor-ine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation 1999; 67: 499.
12. Martino R, Caballero MD, Canals C, Simon JA, Solano C, Urbano-Ispzua A et al. Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. Br J Haematol 2001; 115: 653-659. (Pubitemid 34015658)
13. Perez-Simon JA, Dez-Campelo M, Martino R, Brunet S, Urbano A, Caballero MD et al. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. Br J Haematol 2005; 130: 394-403.
14. Przepiorka D, Weisdorf D, Martin P. Meeting report consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
15. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: i. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956. (Pubitemid 41754712)
16. Valcarcel D, Martino R, Caballero D, Mateos MV, Perez-Simon JA, Canals C et al. Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reducedintensity conditioning. Bone Marrow Transplant 2003; 31: 387-392.
17. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: Unadjusted analysis. Bone Marrow Transplant 2001; 28: 909-915. (Pubitemid 33130231)
18. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: Regression modeling. Bone Marrow Transplant 2001; 28: 1001-1011. (Pubitemid 34030645)
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 457-481.
20. Baron F, Maris MB, Sandmaier BM, Storer BE, Sorror M, Diaconescu R et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005; 23: 1993-2003. (Pubitemid 46211379)
21. Kiehl MG, Schafer-Eckart K, Kroger M, Bornhauser M, Basara N, Blau IW et al. Mycophenolate mofetil for the prophylaxis of acute graft-versus-host disease in stem cell transplant recipients. Transplant Proc 2002; 34: 2922-2924.
22. Van Leeuwen L, Guiffre AK, Sewell WA, Vos BJ, Rainer S, Atkinson K et al. Administration of mycophenolate mofetil in a murine model of acute graft-versus-host disease after bone marrow transplantation. Transplantation 1997; 64: 1001-1097.
23. Simmons WD, Rayhill SC, Sollinger HW. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection. Drug Safety 1997; 17: 75-92.
24. Flynn CM, Hirsch B, Defor T, Barker JN, Miller JS, Wagner JE et al. Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis. Am J Hematol 2007; 82: 867-872.
25. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175-181.
26. Champlin RE, Schmitz N, Horowitz MM, Chapuis B, Chopra R, Cornelissen JJ et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood 2000; 95: 3702-3709.
27. Van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001; 23: 119-128.
28. Lange S, Mueller SC, Altmann S, Dahlhaus M, Drewelow B, Freund M et al. Pharmacokinetics of oral mycophenolate mofetil in combination with CsA in dogs after nonmyelo-ablative allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 41: 667-674.
29. Perez-Simon JA, Martino R, Caballero D, Valcarcel D, Rebollo N, de la Camara R et al. Grupo espanol de trasplante hematopoyetico GETH. Reduced-intensity conditioning allo-geneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin a as graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 2008; 14: 664-671.
30. Giaccone L, McCune JS, Maris MB, Gooley TA, Sandmaier BM, Slattery JT et al. Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. Blood 2005; 106: 4381.
31. Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem HP et al. Stable mixed hematopoietic chimerism in dla-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89: 3048-3054.
32. Gomez-Nunez M, Martino R, Caballero MD, Perez-Simon JA, Canals C, Mateos MV et al. Elderly age and prior autologous transplantation have a deleterious effect on survival following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results from the Spanish multicenter prospective trial. Bone Marrow Transplant 2004; 33: 477-482.
33. Michallet M, Le QH, Mohty M, Prebet T, Nicolini F, Boiron JM et al. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Societe FranCaise de Greffe de Moelle et de Therapie Cellulaire. Exp Hematol 2008; 36: 535-544.
34. Van Besien KW, Mehra RC, Giralt SA, Kantarjian HM, Pugh WC, Khouri IF et al. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. Am J Med 1996; 100: 299-307.
35. Bearman SI, Appelbaum FR, Back A, Petersen FB, Buckner CD, Sullivan KM et al. Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma. J Clin Oncol 1989; 7: 1288-1294.
36. Mohty M, Fegueux N, Exbrayat C, Lu ZY, Legouffe E, Quittet P et al. Reduced intensity conditioning: enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy. Bone Marrow Transplant 2001; 28: 335-339.